Impact of Long-Acting Somatostatin Analogues on Glucose Metabolism in Acromegaly: A Hospital-Based Study
Table 2
Comparison of baseline characteristics of patients in the Improved/Stable/Deteriorated glucose tolerance status groups.
Change in glucose status
value
Improved ()
Stable ()
Deteriorated ()
Female [n/(%)]
11 (61.1)
17 (60.7)
10 (55.6)
0.927
Age (years)
38.4 ± 9.7
46.1 ± 13.2
38.1 ± 13.7
0.049∧
BMI (kg/m2)
21.99 ± 8.32
24.79 ± 6.26
24.99 ± 7.79
0.378
GHm (μg/l)
40.72 (25.88~86.15)
27.98 (15.69~70.23)
22.61 (12.65~49.69)
0.172
IGF-1 index
2.87 ± 1.05
2.94 ± 0.89
2.58 ± 0.65
0.489
HbA1c (%)
5.80 (5.50~6.25)
6.30 (5.60~9.18)
5.70 (5.60~5.88)
0.196
FPG (mmol/l)
5.50 (5.18~6.18)
5.75 (5.03~6.70)
5.30 (5.10~5.80)
0.254
BG120 (mmol/l)
9.25 (8.68~12.73)
11.40 (7.83~17.13)
6.80 (5.58~8.23)
<0.001∧
FPI (mU/l)
17.65 (11.55~26.38)
13.02 (8.66~23.53)
16.40 (12.13~30.58)
0.329
INS120 (mU/l)
174.05 (63.53~248.98)
69.80 (25.18~152.33)
73.65 (48.90~189.85)
0.166
IGF-1 index: the ratio of the measured IGF-1 value to the upper limit of normal (ULN); HbA1c: glycosylated hemoglobin; FPG: fasting plasma glucose; BG120: plasma glucose 120 min during OGTT; FPI: fasting plasma insulin; INS120: plasma insulin 120 min during OGTT; values are for variations among the 3 groups; .
